At Blueprint Medicines, we are motivated by one goal: to dramatically improve the lives of people with cancer and other debilitating diseases.

We do that through our singular focus on kinases, a class of proteins that regulate many of the body’s cellular processes and play a critical role in virtually all aspects of cancer. We draw on a deep understanding of kinase biology, identifying abnormalities in kinase activity that drives the growth and development of specific diseases. Then, we craft medicines that are precisely targeted against those disease drivers.

By identifying patients whose disease is driven by the targeted abnormality, we believe we can deliver breakthrough medicines to patients that allow them to live longer lives with better quality and that prevent recurrences of disease.
We are currently advancing multiple therapies in clinical studies for defined subsets of patients, based on the genomic and molecular profile of their disease, in hepatocellular carcinoma (HCC), refractory or treatment-resistant gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM).

We invite you to learn more about these medicines and the ongoing clinical trials, as well as to explore a select list of resources for these diseases.


Jeffrey W. Albers
CEO, President and member of the
Board of Directors